Drug Patents owned by Aaa Usa Inc
1. List of Lutathera drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10596276 | AAA USA INC | Stable, concentrated radionuclide complex solutions |
Jul, 2038
(15 years from now) | |
| US10596278 | AAA USA INC | Stable, concentrated radionuclide complex solutions |
Jul, 2038
(15 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jan 26, 2023 |
| Orphan Drug Exclusivity (ODE) | Jan 26, 2025 |
Drugs and Companies using LUTETIUM DOTATATE LU-177 ingredient
NCE-1 date: 2022-01-26
Market Authorisation Date: 26 January, 2018
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
LUTATHERA family patents
10
United States
4
Japan
4
European Union
3
IB
3
China
2
Australia
1
Israel
1
Germany
1
Colombia
1
Argentina
1
Brazil
1
Singapore
1
Canada
1
Korea, Republic of
1
Taiwan, Province of China
2. List of Netspot drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9375498 | AAA USA INC | Process for the preparation of complexes of 68Ga |
Aug, 2032
(9 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Jun 1, 2023 |
Drugs and Companies using GALLIUM DOTATATE GA-68 ingredient
Market Authorisation Date: 01 June, 2016
Treatment: NA
Dosage: POWDER;INTRAVENOUS
NETSPOT family patents
4
European Union
3
Israel
3
Russia
3
United States
2
Brazil
2
Spain
2
Canada
2
New Zealand
1
South Africa
1
Denmark
1
Mexico
1
Australia
1
Colombia
1
Portugal
1
Italy
1
Poland
1
India
1
China
1
Japan
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic